CytomX Therapeutics (CTMX) Current Deferred Revenue (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Current Deferred Revenue came in at $18.9 million in Q1 2026, down 61.86% YoY from $49.4 million in Q1 2025, and down 29.85% on a QoQ basis from $26.9 million in Q4 2025.
CytomX Therapeutics (CTMX) Current Deferred Revenue (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Current Deferred Revenue data on file, last reported at $18.9 million in Q1 2026.
- Quarterly Current Deferred Revenue fell 61.86% year-over-year to $18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.9 million (down 61.86% YoY) and the FY2025 annual result came in at $26.9 million, down 71.43% from the prior year.
- Current Deferred Revenue slipped to $18.9 million in Q1 2026, from $26.9 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $301.3 million in Q4 2022 to a low of $4.0 million in Q1 2023.
- A 5-year average of $147.6 million and a median of $160.5 million in 2024 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2023 — Current Deferred Revenue tumbled 98.55% — and 2024, when it surged 4484.28%.
- Tracing CTMX's Current Deferred Revenue over 5 years: stood at $301.3 million in 2022, then retreated by 29.54% to $212.3 million in 2023, then plunged by 55.7% to $94.1 million in 2024, then plunged by 71.43% to $26.9 million in 2025, then fell by 29.85% to $18.9 million in 2026.
- The last three Current Deferred Revenue figures came in at $18.9 million (Q1 2026), $26.9 million (Q4 2025), and $22.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.70 Mn |
| Mar 31, 2026 | 18.86 Mn |
| Dec 31, 2025 | 26.88 Mn |
| Sep 30, 2025 | 22.38 Mn |
| Jun 30, 2025 | 11.60 Mn |
| Mar 31, 2025 | 49.44 Mn |
| Dec 31, 2024 | 94.06 Mn |
| Sep 30, 2024 | 129.62 Mn |
| Jun 30, 2024 | 160.48 Mn |
| Mar 31, 2024 | 183.37 Mn |
| Dec 31, 2023 | 212.32 Mn |
| Sep 30, 2023 | 236.66 Mn |
| Jun 30, 2023 | 261.15 Mn |
| Mar 31, 2023 | 4.00 Mn |
| Dec 31, 2022 | 301.33 Mn |
| Sep 30, 2022 | 255.46 Mn |
| Jun 30, 2022 | 264.90 Mn |
| Mar 31, 2022 | 276.73 Mn |
| Dec 31, 2021 | 284.76 Mn |
| Sep 30, 2021 | 40.84 Mn |